Nuvisan provides fully integrated drug discovery and early development services. In this talk, we will highlight our capabilities and track record by presenting insights into a recent program targeting KRAS: • Combination of high-throughput and fragment screening enabled a new approach to target KRAS, • Guidance by intensive structural biology efforts and multiple biophysics approaches, • Discovery of nanomolar, selective and cellularly active SOS1 inhibitors.
To view the video assoicated with this lecture
click here
